Opinion
Video
Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.
Patients With ILD Face Higher Burden of Fatigue, Excessive Daytime Sleepiness
Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa
COPD Linked to Increased Risk of Cognitive Impairment
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
Rare Blood Disease Innovations Address Unmet Needs, According to ASH Data
Molecular Lesions in Low-Risk Myelodysplastic Neoplasms Disrupt Prognostic Model for Leukemia